Membrane subproteomic analysis of Mycobacterium bovis bacillus Calmette-Guérin

Authors

  • Jianhua Zheng,

    1. College of Biological Sciences, China Agricultural University, Beijing, P. R. China
    2. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
    • Both these authors contributed equally to this work.

  • Candong Wei,

    1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
    • Both these authors contributed equally to this work.

  • Wenchuan Leng,

    1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
  • Jie Dong,

    1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
  • Rui Li,

    1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
  • Weijun Li,

    1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
  • Jin Wang,

    1. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    Search for more papers by this author
  • Zongde Zhang,

    1. Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, P. R. China
    Search for more papers by this author
  • Qi Jin Professor

    Corresponding author
    1. College of Biological Sciences, China Agricultural University, Beijing, P. R. China
    2. State Key Laboratory for Molecular Virology and Genetic Engineering, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, P. R. China
    3. Institute of Pathogen Biology, Chinese Academy of Medical Sciences, Beijing, P. R. China
    • State Key Laboratory for Molecular Virology and Genetic Engineering, No. 6 Rongjing East Street, BDA, Beijing 100176, P. R. China Fax: +86-10-67877736
    Search for more papers by this author

Abstract

Mycobacterium bovis bacillus Calmette–Guérin (BCG) vaccine has been known for a long time to prevent tuberculosis (TB) worldwide since 1921. Nonetheless, we know little about BCG membrane proteome. In the present study, we utilized alkaline incubation and Triton X-114-based methods to enrich BCG membrane proteins and subsequently digested them using proteolytic enzyme. The recovered peptides were further separated by 2-D LC and identified by ESI-MS/MS. As a result, total 474 proteins were identified, including 78 integral membrane proteins (IMPs). Notably, 18 BCG IMPs were described for the first time in mycobacterium. Further analysis of the 78 IMPs indicated that the theoretical molecular mass distribution of them ranged from 8.06 to 167.86 kDa and pI scores ranged from 4.40 to 11.60. Functional classification revealed that a large proportion of the identified IMPs (67.9%, 53 out of 78) were involved in cell wall and cell processes functional group. In conclusion, here we reported a comprehensive profile of the BCG membrane subproteome. The present investigation may allow the identification of some valuable vaccine and drug target candidates and thus provide basement for future designing of preventive, diagnostic, and therapeutic strategies against TB.

Ancillary